These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15110181)

  • 1. TRAIL and viral infection.
    Sträter J; Möller P
    Vitam Horm; 2004; 67():257-74. PubMed ID: 15110181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRAIL and apoptosis induction by TNF-family death receptors.
    Wang S; El-Deiry WS
    Oncogene; 2003 Nov; 22(53):8628-33. PubMed ID: 14634624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
    Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL and chemotherapeutic drugs in cancer therapy.
    Wu XX; Ogawa O; Kakehi Y
    Vitam Horm; 2004; 67():365-83. PubMed ID: 15110186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Death inducing ligands in combination with ionizing radiation: objective and current knowledge].
    Belka C; Betsch A; Marini P; Jendrossek V; Bamberg M; Budach W
    Strahlenther Onkol; 2003 Mar; 179(3):141-51. PubMed ID: 12627256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice.
    Ishikawa E; Nakazawa M; Yoshinari M; Minami M
    J Virol; 2005 Jun; 79(12):7658-63. PubMed ID: 15919918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of TRAIL signaling for cancer therapy.
    Fulda S; Debatin KM
    Vitam Horm; 2004; 67():275-90. PubMed ID: 15110182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
    Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
    J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting death receptors in cancer with Apo2L/TRAIL.
    Kelley SK; Ashkenazi A
    Curr Opin Pharmacol; 2004 Aug; 4(4):333-9. PubMed ID: 15251125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.
    Izeradjene K; Douglas L; Delaney AB; Houghton JA
    Cancer Res; 2004 Nov; 64(21):8036-44. PubMed ID: 15520213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins.
    Mirandola P; Sponzilli I; Gobbi G; Marmiroli S; Rinaldi L; Binazzi R; Piccari GG; Ramazzotti G; Gaboardi GC; Cocco L; Vitale M
    Int J Oncol; 2006 Jan; 28(1):127-33. PubMed ID: 16327988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
    Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
    Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor and trail interactions in epithelial-derived cells.
    Gibson SB
    Vitam Horm; 2004; 67():207-27. PubMed ID: 15110179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors.
    Wenger T; Mattern J; Penzel R; Gassler N; Haas TL; Sprick MR; Walczak H; Krammer PH; Debatin KM; Herr I
    Cell Death Differ; 2006 Oct; 13(10):1740-51. PubMed ID: 16470224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
    Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
    Kumamoto H; Ooya K
    J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis.
    Mori E; Thomas M; Motoki K; Kataika S
    FEBS Lett; 2005 Oct; 579(24):5379-84. PubMed ID: 16199041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy.
    Odoux C; Albers A
    Vitam Horm; 2004; 67():385-407. PubMed ID: 15110187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.